Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP trimmed its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 0.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,422,566 shares of the company’s stock after selling 21,848 shares during the quarter. Wellington Management Group LLP owned approximately 1.57% of Hims & Hers Health worth $82,758,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in HIMS. Crewe Advisors LLC acquired a new stake in Hims & Hers Health during the 4th quarter worth $28,000. Raleigh Capital Management Inc. boosted its position in Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 1,100 shares during the last quarter. Blume Capital Management Inc. grew its stake in Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 600 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after acquiring an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC purchased a new position in Hims & Hers Health in the 4th quarter worth approximately $38,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 36,460 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $27.09, for a total transaction of $987,701.40. Following the sale, the chief executive officer now directly owns 27,918 shares in the company, valued at $756,298.62. This represents a 56.63 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Irene Becklund sold 2,203 shares of the business’s stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total transaction of $63,402.34. Following the completion of the transaction, the insider now owns 8,007 shares of the company’s stock, valued at approximately $230,441.46. This trade represents a 21.58 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,078,738 shares of company stock valued at $38,386,521. 17.71% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Piper Sandler upped their price target on Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, February 25th. Leerink Partners raised their target price on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research note on Tuesday, February 25th. Truist Financial boosted their price target on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a research report on Wednesday, February 26th. Canaccord Genuity Group raised their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Finally, Needham & Company LLC boosted their target price on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $37.31.

Hims & Hers Health Stock Down 7.4 %

Shares of NYSE HIMS opened at $25.93 on Friday. The business’s 50 day moving average is $39.82 and its two-hundred day moving average is $29.84. Hims & Hers Health, Inc. has a 52-week low of $11.20 and a 52-week high of $72.98. The firm has a market cap of $5.76 billion, a price-to-earnings ratio of 58.93 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.